読み込み中
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
前日終値
$7.82
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日中レンジ
現在 $7.82
52週レンジ
現在 $7.82
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
38
割高
センチメント
60
まちまち
リスク
75
高リスク
モメンタム
27
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
日中レンジ
現在 $7.82
52週レンジ
現在 $7.82
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1.58億 USD | 1.25億 USD | 8614万 USD | 8227.4万 USD | 5110万 USD |
| 販売・一般管理 | 2100.1万 USD | 1774.1万 USD | 1882.1万 USD | 2471.4万 USD | 2039.1万 USD |
| 営業費用 | 1.79億 USD | 1.42億 USD | 1.05億 USD | 1.07億 USD | 7149.1万 USD |
| 受取利息 | 1622.4万 USD | 1268.2万 USD | 832.5万 USD | 222.8万 USD | 44.2万 USD |
| 減価償却費と償却費 | 49万 USD | 39.3万 USD | 37.7万 USD | 35.7万 USD | 16.3万 USD |
| 営業利益 | −1.79億 USD | −1.42億 USD | −1.05億 USD | −1.07億 USD | −7149.1万 USD |
| 純利益 | −1.62億 USD | −1.29億 USD | −9665.5万 USD | −1.05億 USD | −7109.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$28.33
上昇余地（262.28%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2723.58万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1700.15万0.17%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1614.54万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF687.92万0.01%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO469.92万0.03%180億 USD0.06%$112.66+0.50%
Dimensional - US Small Cap ETFDFAS446.39万0.01%338.69億 USD0.31%$78.35+0.32%
iShares Biotechnology ETFIBB425.84万0.04%108.2億 USD0.44%$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM369.04万0.06%64.1億 USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
